Revvity, Inc. (NYSE:RVTY) Short Interest Update

Revvity, Inc. (NYSE:RVTY) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 3,600,000 shares, an increase of 33.8% from the March 31st total of 2,690,000 shares. Approximately 2.9% of the company’s stock are sold short. Based on an average trading volume of 888,500 shares, the short-interest ratio is currently 4.1 days.

Revvity Trading Down 0.6 %

RVTY opened at $101.51 on Friday. The stock’s fifty day moving average is $104.66 and its two-hundred day moving average is $101.40. The company has a market capitalization of $12.54 billion, a P/E ratio of 18.46, a PEG ratio of 2.64 and a beta of 1.09. Revvity has a 52 week low of $79.50 and a 52 week high of $132.54. The company has a quick ratio of 1.77, a current ratio of 2.07 and a debt-to-equity ratio of 0.40.

Revvity (NYSE:RVTY) last released its quarterly earnings data on Thursday, February 1st. The company reported $1.25 EPS for the quarter, topping the consensus estimate of $1.15 by $0.10. The company had revenue of $695.90 million for the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Analysts forecast that Revvity will post 4.65 earnings per share for the current year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, August 9th. Stockholders of record on Friday, July 19th will be given a $0.07 dividend. The ex-dividend date of this dividend is Friday, July 19th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.28%. Revvity’s payout ratio is 5.09%.

Insiders Place Their Bets

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the sale, the insider now owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Revvity

A number of institutional investors have recently made changes to their positions in RVTY. Parkside Financial Bank & Trust acquired a new stake in shares of Revvity in the 4th quarter worth $25,000. Gladius Capital Management LP boosted its position in shares of Revvity by 84.1% in the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares in the last quarter. CENTRAL TRUST Co acquired a new stake in shares of Revvity in the 4th quarter worth $27,000. Benjamin F. Edwards & Company Inc. acquired a new stake in shares of Revvity in the 4th quarter worth $27,000. Finally, ORG Partners LLC acquired a new stake in shares of Revvity in the 4th quarter worth $32,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on RVTY. KeyCorp boosted their price objective on shares of Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. Stifel Nicolaus upped their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Evercore ISI raised shares of Revvity from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $88.00 to $125.00 in a report on Thursday, January 4th. UBS Group downgraded Revvity from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, Barclays raised their price target on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, January 25th. Six research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $118.91.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.